Novavax Seeks Full FDA Approval for COVID-19 Vaccine

In our recent interview with Novavax’s Chief Medical Officer, Robert Walker, MD, he discussed the company’s progress in obtaining full licensure for their COVID-19 vaccine. He said, “We've submitted a Biologics License Application (BLA) to the FDA to seek full licensure for our vaccine, which is currently available under Emergency Use Authorization (EUA). The PDUFA date is the date the FDA expects to have its review completed and issue a final decision. Of course, we’re very much looking forward to obtaining full licensure of our vaccine, achieving parity with the other COVID-19 vaccines available.”

When asked about the timeline for the FDA’s decision, Walker provided an update on the current status, “We’re in the end of January now, and hopefully it won’t be too much longer until we get the full licensure. We’re working very closely with the FDA to make sure they get all their questions answered, and that they understand all the data we've provided in the application.”

With the review process underway, the company remains hopeful that the vaccine will soon receive full licensure, making it a mainstream option for those who prefer a protein-based vaccine over mRNA alternatives.

As the pandemic continues to impact global health, Walker reminded the public of the importance of staying vigilant, “COVID is still very much with us, and it’s really important to protect ourselves, our families, and our communities. I encourage everyone to get vaccinated. If you're in a high-risk group, make sure to get your revaccination. And above all, stay healthy.”

Reference

Novavax. Novavax continues to partner with the U.S. FDA on review of 2024-2025 formula COVID-19 vaccine. Updated August 23, 2024. Accessed February 6, 2025. https://ir.novavax.com/press-releases/Novavax-Continues-to-Work-with-the-US-FDA-on-Authorization-of-2024-2025-Formula-COVID-19-Vaccine